Co-stimulation of cancer vaccines with peptides improves efficiency
2016
Copenhagen University Hospital, Copenhagen, Denmark
Programmed death 1 (PD-1) is expressed on the surface of T cells and its ligands play a central role in maintaining peripheral tolerance and preventing autoimmunity. Cancer cells can exploit this system to create a suppressing microenvironment, thus protecting themselves from immune-mediated killing. Indeed, PD-L1 expression has been found to be high in multiple cancers. In the present study, the researchers used peripheral blood from patients with malignant melanoma who had been treated with dendritic cell (DC)-based vaccine. The cells were used to co-stimulate the vaccine with PD-L1-derived epitopes. Co-stimulation boosted the immune response elicited by the DC vaccine. A significant increase in the number of vaccine-reacting T cells was observed in vitro. In conclusion, activation of PD-L1-specific T cells may directly modulate the immunogenicity of DC vaccines and may be an attractive option to improve the efficiency of immunotherapeutic agents.
PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine
Mads Hald Andersen
Added on: 07-28-2021
[1] https://www.tandfonline.com/doi/full/10.1080/2162402X.2016.1202391[2] https://data.jrc.ec.europa.eu/dataset/352f7dfd-05cf-434b-a96a-7e270dc76573
